FCGR3A and plasma cell myeloma: Elotuzumab is a humanized anti-SLAMF7 (signaling-lymphocyte-activating molecule F7) monoclonal antibody that targets SLAMF7 on myeloma cells and can lead ADCC via CD16 on NK cells and ADCP by macrophages [141].